Loading quotes...
Forecast
There is no analyst data available for this company.
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
CSL writes down around $5 billion and lowers FY26 guidance
CSL is taking a one‑off impairment of about $5 billion on intangibles from the acquisition of CSL Vifor and has cut its adjusted earnings guidance for FY26 to $3.1–3.2 billion, with expected revenue of roughly $15.2 billion. The shares plunged; results are being hit by inventory normalization for immunoglobulins in the US, price declines for albumin in China, and increased competitive and geopolitical pressure. Management plans a transformation program targeting $500–550 million in annual savings by 2028, while market observers are assessing whether cuts could slow mRNA research (including collaborations via CSL Seqirus/CureVac) and thereby hand competitive advantages to BioNTech. » More on finanzen.net
CSL to spin off Seqirus as US vaccine fatigue fades, CEO says
CSL CEO Paul McKenzie said the time is right to spin off its Seqirus business as vaccine demand grows and US vaccine "fatigue" eases, particularly among older people. The announcement comes after CSL's shares plunged the most in 23 years following disappointing earnings results. » More on finance.yahoo.com
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 6.52bn | - |
| Gross profit | 2.89bn | - |
| Net profit | -2.62bn | - |
| EBITDA | 1.72bn | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €121.03bn |
Number of shares | 3.87bn |
52-week high/low | €33.50 - €14.54 |
Dividend yield | 2.00% |
Dividends TTM | €0.62 |
Beta | 0.08 |
P/E ratio | -25.84 |
PEG ratio | 0.14 |
P/B ratio | 4.43 |
P/S ratio | 4.17 |
Company profile
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
| Name | CSL ADR |
| CEO | Gordon Naylor DipCompSc |
| Headquarters | Melbourne,
vic Australia |
| Website | |
| IPO | 07/10/2020 |
| Employees | 29,000 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
Pnk | CSLLY |
Frankfurt | CSJA.F |
Düsseldorf | CSJA.DU |
München | CSJA.MU |